There is also circumstantial evidence implicating HER3 in drug resistance—it is induced and activated in BM from breast and lung cancers, and has been separately implicated in resistance to anti-oestrogen, -HER2 and cytotoxic therapies [83,84,85,86,87]. Here, ERBB3 is linked to lung cancer.